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Oxidative stress and renal injury with intravenous iron in pa-
tients with chronic kidney disease.
Background. Intravenous iron is widely prescribed in patients
with chronic kidney disease (CKD) and can cause oxidative
stress. The relationship of oxidative stress and renal injury in
patients with CKD is unknown. Whether renal injury can occur
at a time point when transferrin is incompletely saturated is also
unclear.
Methods. We conducted a randomized, open-label, parallel
group trial to compare the oxidative stress induced by intra-
venous administration of 100 mg iron sucrose over 5 minutes
and its protection with N-acetylcysteine (NAC) in 20 sub-
jects with stage 3 or 4 CKD. Transferrin saturation was
measured with urea polyacrylamide gel electrophoresis, ox-
idative stress by malondialdehyde (MDA) measurement by
high-performance liquid chromatography, and renal injury
by enzymuria and proteinuria. Reduced and oxidized glu-
tathione and free radical scavengers as well as urinary monocyte
chemoattractant protein-1 were also measured.
Results. Parenteral iron increased plasma concentration and
urinary excretion rate of MDA, a biomarker of lipid peroxida-
tion, within 15 to 30 minutes of iron sucrose administration. This
was accompanied by enzymuria and increase in proteinuria. In
contrast, saturation of transferrin was not maximally seen until
3 hours after the end of infusion. Oxidative stress, enzymuria
and proteinuria were transient and were completely resolved in
24 hours. NAC reduced acute generation of systemic oxidative
stress but failed to abrogate proteinuria or enzymuria.
Conclusion. Intravenous iron produces oxidative stress that
is associated with transient proteinuria and tubular damage.
The rapid production of oxidative stress even when transfer-
rin is not completely saturation suggests free iron independent
mechanism(s) to be operative in producing oxidative stress and
transient renal injury. Long-term implications of these findings
need further study.
In the United States there are approximately 8 mil-
lion individuals with moderate to severe chronic kid-
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ney disease (CKD), not on dialysis [1]. Anemia sets in
early during the course of renal disease, either as a re-
sult of erythropoietin deficiency or due to insufficient ab-
sorption of dietary iron [2]. Furthermore, a functional
deficiency of iron may occur due to enhanced erythro-
poiesis after therapy with recombinant human erythro-
poietin that often necessitates therapy with intravenous
iron [3]. The correction of anemia leads to improvement
in morbidity, mortality, and quality of life [4]; however,
potential toxicity due to the participation of elemen-
tal iron in oxidation-reduction reactions has raised con-
cern of potential risks of this commonly utilized therapy
[5, 6].
Oxidative stress plays an important role in the patho-
genesis and progression of renal disease [7, 8]. Intra-
venous iron has been shown to increase biologic markers
of oxidative stress [9] in cell cultures [10], animal mod-
els [11], and end-stage renal disease (ESRD) patients on
hemodialysis [12–14]. Intravenous administration of iron
sucrose in dialysis patients results in an increase in total
peroxide, free iron, and markers of lipid peroxidation,
and is significantly improved with the antioxidant, vita-
min E [15]. Whether patients with CKD not on dialy-
sis have a similar increase in oxidative stress and, above
all, renal injury upon exposure to intravenous iron is un-
known. This knowledge is of critical importance because
oxidative stress and renal injury may lead to an acceler-
ated course of renal [7] and cardiovascular disease [16,
17]. Furthermore, it is unknown whether the acute ox-
idative stress imposed by iron can be reduced with an-
tioxidant therapy. In this context, animal and human data
demonstrate beneficial effects of N-acetylcysteine (NAC)
in models of oxidative stress such as contrast-induced
acute renal failure [18].
We hypothesized that in subjects with moderate to se-
vere CKD, an infusion of intravenous iron would gen-
erate oxidative stress and that this would cause tubular
injury and increase in glomerular permeability. Further-
more, the generation of oxidative stress, tubular injury,
glomerular permeability, and renal inflammation would
be mitigated by therapy with the antioxidant NAC.
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METHODS
Subjects
Study participants were recruited from the Nephrol-
ogy Clinic at the Richard L. Roudebush VA Medical
Center. Subjects were at least 18 years in age, had an
estimated glomerular filtration rate (GFR) ≤ 60 mL/min
by the six-component Modified Diet in Renal Disease
(MDRD) Study formula [19] but were not on renal
replacement therapy and had iron deficiency anemia.
Anemia was defined as blood hemoglobin concentration
below the 95th percentile in the NHANES evaluation
[20]. Iron deficiency was defined using National Kidney
Foundation/Kidney Disease Outcome Quality Initiative
(NKF-K/DOQI) guidelines as having a serum ferritin
concentration of <100 ng/mL or serum transferrin satu-
ration of <20% [21]. Subjects were excluded if they were
hypersensitive to iron sucrose or NAC, were an organ
transplant recipient or received therapy with immuno-
suppressive agents, used an investigational drug 1 month
prior to study, or demonstrated the presence of active
asthma, human immunodeficiency virus (HIV), cancer,
rheumatoid arthritis, alcoholism, or liver disease. Sub-
jects were also excluded if they were anemic such that ery-
throcyte transfusion was imminent (hemoglobin <8 g/dL,
or active gastrointestinal bleeding), had acute renal fail-
ure, defined as an increase in the baseline serum crea-
tinine concentration of ≥0.5 mg/dL over 48 hours, were
pregnant or breastfeeding, had received intravenous iron
within 3 months of the study, demonstrated iron over-
load (serum ferritin >800 ng/mL or transferrin satura-
tion >50%), had anemia not caused by iron deficiency,
had surgery or systemic or urinary tract infection within
1 month of study, or a serum albumin <3.0 g/dL.
The protocol was approved by the Institutional Review
Board at Indiana University School of Medicine and the
Research and Development Committee of the Richard
L. Roudebush VA Medical Center. Written informed
consent was obtained from each subject prior to study
participation.
Study design
Subjects who satisfied the inclusion and exclusion crite-
ria were assigned by a computer-generated randomized
block randomization scheme to one of two open-label,
1-week, parallel treatment arms: either no active in-
tervention, or treatment with the antioxidant NAC
(Mucomyst) (Apothecon, Inc., Princeton, NJ, USA) at
a dose of 600 mg twice a day. The allocation scheme was
concealed from investigators until time of subject ran-
domization. Oral iron supplements were stopped for the
duration of the study.
The trial design is illustrated in Figure 1. Subjects were
requested to be fasting before all visits. During the ini-
tial study period, baseline blood and urine was collected
and assayed for biomarkers of lipid peroxidation [plasma
and urine malondialdehyde (MDA)], substrate for lipid
peroxidation (lipid panel), evaluation of iron deficiency
anemia [complete blood count, iron, total iron bind-
ing capacity (TIBC), ferritin], redox state [plasma and
erythrocyte oxidized and reduced glutathione (GSSG,
GSH)], free radical scavengers [erythrocyte superox-
ide dismutase (red blood cell SOD) and glutathione
peroxidase (GSHPx)], and markers of renal tubular
and glomerular damage and/or inflammation [urinary
monocyte chemoattractant protein-1 (MCP-1), urine to-
tal protein, and N-acetyl-b-D-glucosaminidase (NAG)].
Subjects then received an intravenous dose of iron su-
crose (Venofer) (American Regent Laboratories, Inc.,
Shirley, NY, USA) at a dose of 100 mg infused over
5 minutes. Blood and urine collections were obtained at
baseline, 0.25, 0.5, 1, 2, 3, and 24 hours after iron dosing to
assay for the above parameters. During the visits, the sub-
jects completed the Kidney Disease and Quality of Life
Short Form (KDQOL-SF, version 1.3). Subjects were ran-
domized to take either no additional treatment or NAC
600 mg twice a day for 1 week. The last dose of NAC was
administered under direct supervision by the study nurse
in the morning of the second infusion of intravenous iron.
After 1 week, subjects had all study procedures repeated
as on the initial study period. NAC-assigned subjects re-
turned with remaining antioxidant doses to assess com-
pliance. Subjects completed a KDQOL-SF modified to
assess parameters over the 1-week intervening treatment
period.
Laboratory analysis
Electrophoretic separation of transferrins. The iron
forms of transferrin were separated using a urea poly-
acrylamide gel (6% acrylamide gels with 6 mol/L urea)
according to Williams, Evans, and Moreton [22]. This
method separates transferrin into the apotransferrin,
monoferric, and the diferric forms, according to their elec-
trophoretic mobilities. Precipitation of transferrin from
plasma was achieved through treatment with 2% 6,9-
diamino-2-ethoxyacridine lactate monohydrate (Sigma
Chemical Co., St. Louis, MO, USA) and subsequent
centrifugation before being applied to the gel to pre-
cipitate all serum proteins but b and c globulins [23].
Electrophoresis was performed using a Criterion mini-gel
system (Bio-Rad, Hercules, CA, USA). Fourteen plasma
samples obtained from each subject over two visits were
separated simultaneously on the same gel, along with con-
trols of apotransferrin, monoferric transferrin(s), and di-
ferric transferrin. Protein bands were visualized through
staining with GelCode Blue stain reagent (Pierce,
Rockford, IL, USA). Densitometric analysis was per-
formed with a Gel Logic 100 apparatus and one-
dimensional image analysis software (Kodak, Rochester,
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Fig. 1. Trial design. All patients with chronic kidney disease (CKD) had baseline urine and blood draws followed by administration of iron sucrose.
Blood and urine specimens were collected at 0.25, 0.5, 1, 2, 3, and 24 hours after administration of the drug. Patients were then randomized to receive
N-acetylcysteine (NAC) or nothing for 1 week in an open-label fashion. After 1 week, iron sucrose was again administered and tests performed as
done at first visit.
NY, USA). Percent transferrin saturation was calculated
as follows:
Transferrin Saturation(%) =
[Diferric transferrin + (1/2 × monoferric transferrin(s))]
[Apotransferrin + Monoferric transferrin(s) + Diferric transferrin]
Reduced and oxidized glutathione. Determination of
reduced and oxidized glutathione concentrations was
achieved through an isocratic high-performance liquid
chromatography (HPLC) technique. Specimens were
collected, processed, and analyzed as described by
Paroni et al [24]. We modified the method by increas-
ing the flow rate and changing the wash pattern of the
column as described below.
Briefly, the mobile phase consisted of 21 mmol/L pro-
prionate buffer and acetonitrile, 95:5 (vol/vol) pumped
at 2 mL/min. The column was a Merck LiChrospher
RP-18, 5 l with guard placed in a column warmer
set to 37◦C. Following three consecutive samples, the
column was washed for 3 minutes with a solution of
acetonitrile:methanol:water (55:25:20 vol/vol) followed
by re-equilibration with mobile phase for 4 minutes.
The chromatographic system consisted of a Hewlett-
Packard Chromatographic Series 1100 autosampler and
isocratic pump and Hewlett-Packard model 1046A pro-
grammable fluorescence detector (Palo Alto, CA, USA).
The autosampler was programmed to perform precolumn
derivatization with o-phthalaldehyde with peak detection
by fluorescence with an excitation wavelength of 340 nm
and an emission wavelength 420 nm. Peak areas were
determined using a ChromJet integrator (Thermo Sepa-
ration Products, San Jose, CA, USA).
Plasma and urinary MDA assay. MDA, a lipid hy-
droperoxide, is formed by b-scission of peroxidized
polyunsaturated fatty acids was measured by derivatiza-
tion with thiobarbituric acid (TBA) as reported previ-
ously [25]. Briefly, the mobile phase consisted of 40:60
ratio (vol/vol) of methanol to 50 mmol/L potassium
monobasic phosphate at pH 6.8, pumped at a rate of
1.0 mL/min on a Hewlett-Packard Hypersil 5 l ODS
100 × 4.6 mm placed in a column warmer set to 37◦C.
Samples of plasma and urine were treated with the an-
tioxidant, butylated hydroxytoluene (to prevent in vitro
oxidation) and heat derivatized at 100◦C for 1 hour with
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TBA at an acid pH. Samples were extracted with n-
butanol and 10 lL of the extract was injected at 1-minute
intervals using an autosampler. The Hewlett-Packard
model 1046A programmable fluorescence detector was
set at excitation of 515 nm and emission of 553 nm. Re-
tention time was 1.87 minutes; however, absence of in-
terfering peaks, allows analysis to be carried out in incre-
ments of 1 minute per sample. Within-day variability in
estimation was between 8.6% and 10.3%. Between-days
variability was 3.6% and 7.9%. Recovery was between
88% and 101%.
Urinary MCP-1 assay. MCP-1 was assayed in urine
using a sandwich ELISA (Quantikine kit for Human
MCP-1 Immunoassay) (R&D Systems, Minneapolis, MN,
USA). A standard curve was generated using a four pa-
rameter logistic curve-fit. Corrections were made for con-
centration and values were expressed as pg MCP-1 per
mg creatinine.
SOD and GSHPx activity. SOD activity was measured
in red blood cell lysate using an end point spectropho-
tometric technique (Superoxide Dismutase Assay)
(Cayman Chemical Co., Ann Arbor, MI, USA). GSHPx
activity in red blood cell lysate was determined using an
indirectly coupled reaction with glutathione reductase in
a kinetic spectrophotometric assay (Glutathione Peroxi-
dase Assay) Cayman Chemical Co.).
Urine protein, creatinine, and NAG determination.
Concentration of urinary protein was quantified through
an end point spectrophotometric assay utilizing pyro-
gallol red-molybdate (quanTtest red) (Quantimetrix,
Redondo Beach, CA, USA). Urine creatinine concen-
tration was determined using an end point spectrophoto-
metric with an alkaline-picrate solution (Creatinine Kit)
(Sigma Diagnostics, St. Louis, MO, USA). Urinary NAG
was measured by colorimetric assay (Roche Diagnostics
Corporation, Indianapolis, IN, USA). Other laboratory
assays were performed using standard methods in the
hospital laboratory.
Statistical analysis
The primary outcome variable of this study was the
time course of urinary MDA, protein and NAG excre-
tion rates, total amount excreted and their relationship
to serum transferrin saturation. Other outcome vari-
ables included the influence of NAC on these parameters.
Treatment effects were analyzed using repeated measures
analysis of variance with time and treatment as indepen-
dent factors. Differences between means was tested by
the least significant difference test. Scales of KDQOL
were analyzed by repeated measures, one-way analysis
of variance (ANOVA). All P values are two sided and
significance set at <0.05. All statistical analyses were per-
formed using Statistica for Windows, version 5.5 (Stat-
Soft, Inc., Tulsa, OK, USA).
Table 1. Baseline characteristics of the study population
Iron Iron sucrose +
sucrose + N-acetylcysteine
placebo (NAC) Overall
Number of patients 10 10 20
Age years 71 ± 5.9 75 ± 7.6 73 ± 7.0
Male number 10 10 20
Whites/Blacks number 8/2 7/3 15/5
Weight kg 93 ± 19.2 97 ± 23.8 96 ± 21.3
Body mass index kg·m2 30 ± 12.5 32 ± 7.6 31 ± 10.1
Tobacco use number
Current 2 2 4
Former 9 8 17
Coronary artery 6 8 14
disease number
Etiology of kidney disease number
Hypertension 3 3 6
Diabetes mellitus 6 6 12
Other 0 1 1
Angiotensin-convering 3 7 10
enzyme (ACE) inhibitor
therapy number
Systolic blood pressure 138 ± 29.0 148 ± 23.4 143 ± 26.1
mm Hg
Diastolic blood pressure 69 ± 10.5 66 ± 11.7 67 ± 11.0
mm Hg
Heart rate beats/min 70 ± 10.1 64 ± 10.7 67 ± 10.6
Modification of Diet in 25 ± 7.1 27 ± 7.4 26 ± 7.2
Renal Disease Study
glomerular filtration
rate mL/min
Angiotensin receptor 5 5 10
blocker therapy number
Erythropoietin therapy 4 2 6
number
Hemoglobin g/dL 11.3 ± 1.1 11.1 ± 0.7 11.2 ± 0.9
Iron lg/dL 60.3 ± 28.8 59.4 ± 19.0 60.3 ± 28.8
Total iron binding 351 ± 92 322 ± 67 336 ± 80
capacity lg/dL
Ferritin ng/mL 85 ± 75 127 ± 100 106 ± 89
Serum albumin g/dL 3.8 ± 0.4 4.0 ± 0.3 4.0 ± 0.4
Total cholesterol mg/dL 151 ± 53.5 160 ± 54.2 155 ± 52.6
Low-density lipoprotein 80 ± 37.1 74 ± 25.7 77 ± 31.2
cholesterol mg/dL
High-density lipoprotein 38 ± 11.8 39 ± 8.3 38 ± 9.9
cholesterol mg/dL
Triglycerides mg/dL 178 ± 112.4 224 ± 155.2 201 ± 134.0
RESULTS
Study participants
Actual subject study participation occurred between
April 2003 and August 2003. Baseline and clinical char-
acteristics are shown in Table 1. Subjects treated with in-
travenous iron with and without NAC were similar with
respect to demographic and clinical characteristics out-
lined. There were no women reflecting the paucity of
women with kidney disease among the veteran popula-
tion. The distribution of the etiology of kidney disease,
age, race, weight, and body mass index were similar. Base-
line hematologic, lipid, and other laboratory characteris-
tics were well matched.
There was no increase in hemoglobin or reticulocytes
over 1 week (Table 2). In fact, there was a small fall
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Table 2. Baseline laboratory parameters before and after treatment
with N-acetylcysteine (NAC) or no antioxidants
Iron sucrose + placebo Iron sucrose + NAC
Pre Post Pre Post
White blood cells 8.0 ± 3.6 7.8 ± 3.4 7.3 ± 1.9 6.7 ± 2.0
×1000/lL
Hemoglobin g/dL 11.3 ± 1.1 11.3 ± 0.9 11.1 ± 0.7 10.8 ± 0.5
Mean corpuscular 84.0 ± 6.2 83.9 ± 6.7 89.5 ± 5.6 89.3 ± 5.5
volume fL
RDW % 15.9 ± 1.6 15.8 ± 1.3 14.6 ± 1.6 14.5 ± 1.7
MCHC g/dL 33.5 ± 0.7 33.8 ± 0.7 34.1 ± 0.8 34.1 ± 0.8
Platelets ×1000/lL 237 ± 95.6 243 ± 91.4 198 ± 40.6 192 ± 38.7
Reticulocytes % 1.9 ± 0.5 1.8 ± 0.3 1.4 ± 0.6 1.4 ± 0.4
Iron lg/dL 59.4 ±28.8 51.9 ±14.7 59.4 ±19.0 54.1 ± 12.8
Total iron binding 351 ± 92.4 368 ± 91.9 322 ± 67.1 317 ± 44.2
capacity lg/dL
Transferrrin 19 ± 6 18 ± 10 17 ± 3 15 ± 5
saturation %
Ferritin ng/lL 85 ± 75.4 91 ± 57.2 127 ± 99.9 169 ± 107.3
Abbreviations are: RDW, red cell distribution width; and MCHC, mean
corpuscular hemoglobin concentration. Data shown are mean ± standard
deviation. None of the changes are statistically significant except in hemoglobin
(fall of 0.26 g/dL, (95% CI 0.5 to 0, P = 0.042) and in serum ferritin (increase of
30.3 ng/mL, 95% CI 17.9 to 42.6 ng/mL, P < 0.001).
in hemoglobin concentration of 0.26 g/dL (P = 0.042).
Serum iron and TIBC were unchanged over 1 week, but
serum ferritin increased by 30.3 ng/mL (P < 0.001).
Time course of transferrin saturation, generation
of oxidative stress, and renal injury
Figure 2 shows the overall results of the trial. Plasma
and urinary MDA (top two rows of plots) increased
rapidly within 30 minutes of administration of intra-
venous iron and were accompanied by an increase in pro-
teinuria and enzymuria (third and fourth rows of plots). In
contrast, transferrin saturation did not peak until 3 hours
and returned to baseline by 24 hours (last row of plots). A
significant effect of time was seen for all variables shown
in Figure 1. Plasma MDA was increased at the 15 and
30 minutes time point and was significantly different from
the remaining levels (ANOVA, P < 0.0001). Urine MDA
and NAG were maximal at 30 minutes and significantly
different from rest of the excretion rates (ANOVA, P <
0.0001). Proteinuria was also maximal at 30 minutes but
the excretion rates at 15 and 60 minutes collection points
were also similar to that at 30 minutes (ANOVA, P <
0.0001). Since there was no effect of NAC and no dif-
ference between the two visits, least square means from
ANOVA and pooled standard errors of the means are
shown in Table 3 to illustrate the time course of the ox-
idative stress, iron saturation, and response.
Effect of NAC on generation of oxidative stress
and renal injury
Compliance with intake of NAC assessed by measuring
the volume of returned drug was 101% ± 8%. Because
oxidative stress occurred within minutes, the area un-
der the curve (AUC) of the plasma MDA concentration
time curves were compared from baseline to 180 minutes.
There was a significant improvement in plasma MDA
generation with NAC (P = 0.048). The AUC between the
two intravenous iron infusions using placebo were 184 ±
244 lmol × min/L and 244 ± 51 lmol × min/L, whereas
with NAC they were 217 ± 60 lmol × min/L and 199 ±
45 lmol × min/L, respectively (Fig. 3, top panels). The
redox ratio measured by plasma oxidized to reduced glu-
tathione remained unaltered with treatment with NAC
(Table 4). The total amount of MDA, protein, and NAC
excreted in urine over the 24 hours in patients treated
with NAC and placebo were unchanged. Although NAC
did not change the 24-hour or the first 3-hour excretion of
urinary MDA, Figure 3 shows that the amount of MDA
excreted from 3 to 24 hours was reduced with NAC from
4.24 ± 2.02 lg to 3.36 ± 1.47 lg compared to 3.50 ± 1.19 lg
to 4.08 ± 1.88 lg following placebo (ANOVA for interac-
tion, P = 0.041). The free radical scavenging enzymes in
the red blood cells such as SOD and GSHPx remained un-
changed with the administration of NAC (Table 4). NAC
was unable to reduce the urinary MCP-1 levels that were
unchanged 1 week after intravenous iron administration
(Table 4).
Changes in kidney disease quality of life
There were no statistically significant changes in
KDQOL, except in the pain scale (Table 5). Despite nee-
dle sticks and intravenous catheters, subjects reported im-
provement in pain (higher number is associated with less
pain) on average 14.5% (95% CI, 0.06 to 28.9, P = 0.049).
A trend toward improvement in physical functioning was
seen 5.25% (95% CI, −1.1 to 11.6, P = 0.10).
Safety and adverse events
There were two serious adverse events seen. One pa-
tient had sudden death the night after the day of infusion.
He had underlying coronary artery disease and the event
was not believed to be related to the study drug. Two pa-
tients had diarrhea thought to be related to the study drug.
One patient had diarrhea about 12 hours after the infu-
sion that was accompanied by bloody stools. The other
patient had diarrhea within 1 hour of administration of
the study drug.
DISCUSSION
The major findings of our study are that oxidative stress
occurs rapidly with infusion of intravenous iron sucrose
in patients with CKD in doses recommended by the man-
ufacturer. Oxidative stress so induced is accompanied
by the occurrence of renal tubular damage and possibly
increase in glomerular permeability as assessed by en-
zymuria and increase in proteinuria, respectively. These
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Fig. 2. Time course of biomarkers of oxidative stress, renal injury, and transferrin saturation. Time refers to the actual time of blood sampling or,
in the case of urinary excretion rates, the midpoint of the sampling interval. Time 0 is the midpoint of injection of iron sucrose. Error bars reflect
standard errors. Abbreviations are: NAC, N-acetylcysteine; MDA, malondialdehyde; NAG, N-acetyl-b-D-glucosaminidase.
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Table 3. Time course of transferrin saturation (TSAT), oxidative stress, and renal injury markers
Plasma Midpoint of urine Urine Urine N-acetyl-b-D-
Time malondialdehyde collection malondialdehyde glucosaminidase Urine protein
minutes TSAT % (MDA) lmol/L minutes (MDA) nmol/min (NAG) mU/min lg/min
0 9.7 ± 2.2 0.89 ± 0.14 −15 2.94 ± 0.24 13.5 ± 1.5 237 (61,914)
15 41.4 ± 5 1.42 ± 0.12 7.5 6.33 ± 0.88 15.1 ± 2.5 312 (80,1219)
30 45.6 ± 5 1.39 ± 0.2 22.5 13.32 ± 1.81 23.4 ± 5.6 337 (73,1566)
60 52 ± 5.1 1.05 ± 0.11 45 9.44 ± 1.79 14.2 ± 3.3 251 (57,1099)
120 63.3 ± 4.8 1.08 ± 0.16 90 6.85 ± 0.78 12.6 ± 2.5 203 (47,883)
180 73 ± 4.8 0.95 ± 0.13 150 7.28 ± 1.01 12.7 ± 3.8 189 (39,916)
1440 34.9 ± 7.3 0.75 ± 0.1 810 3.00 ± 0.39 5.8 ± 1.3 100 (24,424)
Influence of iron sucrose on TSAT, oxidative stress (plasma MDA, urine MDA) and renal injury (urine NAG, urine protein) markers in patients with chronic kidney
disease (CKD). There was a significant treatment time interaction for all parameters. Values are least square mean ± pooled standard error of mean. Urine protein
excretion rates represent geometric means and 95% confidence intervals.
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changes occur at a time when there is substantial fraction
of transferrin available to bind to free iron. Furthermore,
despite some improvement in oxidative stress markers
with NAC, there is no protection from renal injury. Taken
together, these data suggest direct damage to the kid-
ney by the drug, independent of transferrin saturation.
However, these changes are transient and resolve rapidly
within 24 hours.
The time course of transferrin saturation follows what
has been reported by Parkkinen et al [26]. In hemodialy-
sis patients, they reported transferrin saturation to be be-
tween 80% and 90% at 31/2 hours following iron sucrose
administration in dose and duration of infusion that were
identical to our study. Transferrin saturation returned to
normal in 48 hours. Free iron, measured as bleomycin-
detectable iron, was not increased unless transferrin satu-
ration was 80% or more. They reported growth of Staphy-
lococcus epidermidis to be increased when incubated in
serum collected at 31/2 hours and arrested by adding ex-
ogenous apotransferrin strongly implicating the role of
free iron in this process.
In contrast to the findings of bacterial overgrowth in
serum of patients with transferrin saturation, we found
maximal oxidative stress, enzymuria and proteinuria to
occur within 15 to 30 minutes of the infusion. These
data suggest a novel mechanism of injury independent
of transferrin saturation. No further increase in oxida-
tive stress or renal damage was noted beyond the first
30 minutes, despite progressive uptake of iron by trans-
ferrin. The results of the antioxidant, NAC, administra-
tion were mixed. Whereas NAC reduced acute systemic
generation of oxidative stress and delayed renal genera-
tion of oxidative stress, there was no improvement in ei-
ther proteinuria or enzymuria. This further supports the
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Table 4. Parameters related to redox ratio, free radical scavengers, and inflammation
Iron sucrose +
N-acetylcysteine (NAC) Iron sucrose + placebo
Baseline One week Baseline One week
Glutathione peroxidase U/mL red blood cells 4580 ± 1108 4589 ± 1204 4382 ± 1458 4234 ± 1779
Superoxide dismutase (SOD) U/mL red blood cells 6.3 ± 0.5 6.3 ± 0.7 6.6 ± 0.9 6.6 ± 0.8
Oxidized Glutathione % 65 ± 13 59 ± 15 48 ± 13 49 ± 16
24-hour urinary monocyte chemoattractant protein-1 367 ± 424 323 ± 317 422 ± 296 416 ± 477
(MCP-1) after iron infusion pg/mg creatinine
Glutathione peroxidase, SOD, and plasma oxidized glutathione were measured before iron infusion. Urinary MCP-1 was measured in the 24-hour urine specimen
following iron infusion. Data shown are mean ± SD. Baseline and 1 week refer to the time of measurements. These measurements were performed before iron infusion.
Table 5. Kidney disease quality of life before and after 1 week of iron administration
Iron sucrose +
Iron sucrose + placebo N-acetylcysteine (NAC)
Scale Baseline One week Baseline One week
Symptom/problem list 81 ± 12.4 86 ± 10.8 73 ± 14.9 78 ± 13.3
Effects of kidney disease 80 ± 16.0 82 ± 10.9 79 ± 20.9 83 ± 12.4
Burden of kidney disease 69 ± 23.3 72 ± 12.1 74 ± 26.6 75 ± 15.0
Work status 33 ± 35.4 22 ± 36.3 30 ± 35.0 25 ± 35.4
Cognitive function 89 ± 12.3 91.1 ± 11.1 85 ± 19.6 91 ± 10.0
Quality of social interaction 85 ± 18.9 86 ± 13.5 81 ± 14.2 82 ± 20.4
Sleep 65 ± 27.1 72 ± 23.3 55 ± 24.9 68 ± 21.6
Social support 92 ± 11.8 83 ± 32.3 92 ± 14.2 93 ± 11.7
Overall health 53 ± 22.9 59 ± 20.3 54 ± 23.2 55 ± 22.2
Physical functioning 26 ± 22.0 38 ± 27.9 29 ± 26.3 35 ± 28.1
Role limitations—physical 30 ± 35.0 33 ± 35.4 20 ± 32.9 43 ± 45.7
Pain 46 ± 21.2 68 ± 25.1 50 ± 28.1 64 ± 30.1
General health 43 ± 14.6 38 ± 15.4 40 ± 21.7 41 ± 23.1
Emotional well-being 83 ± 15.6 78 ± 14.3 79 ± 19.2 85 ± 11.1
Role limitations—emotional 60 ± 46.6 59 ± 32.4 93 ± 14.1 80 ± 35.8
Social function 68 ± 34.0 78 ± 19.5 64 ± 30.3 76 ± 32.5
Energy/fatigue 33 ± 16.0 33 ± 21.5 27 ± 20.0 28 ± 21.1
SF-12 Physical Health Composite 29 ± 8.6 33 ± 10.9 27 ± 6.0 36 ± 7.7
SF-12 Mental Health Composite 53 ± 9.9 48 ± 7.8 54 ± 7.8 53 ± 7.6
Data are mean ± standard deviation. No interaction effect between iron infusion and use of antioxidant was seen. There was significant improvement in pain subscale,
but no other statistical change.
hypothesis that iron sucrose caused damage not simply by
increasing oxidative stress and/or free iron but also per-
haps by a direct cytotoxic effect on the renal tubules. This
may be due to direct effect of the drug on the glomerular
permeability and tubular integrity. Danielson et al [27]
have reported 5% of iron sucrose to be excreted in the
urine, which probably is much greater in patients with im-
paired renal permselectivity, providing rationale of direct
delivery of this drug to the kidney and renal injury. Prox-
imal tubular injury manifested by renal phosphate leak,
calcitriol deficiency, and overt osteomalacia has been re-
ported by Sato and Shiraki [28] that suggest that renal
tubular injury may well become chronic.
Our results are in agreement with previous work that
shows rapid generation of in vitro superoxide produc-
tion after infusion of iron sucrose in normal volunteers
[29]. Although nontransferrin-bound iron continued to
increase over 4 hours, maximal superoxide generation
and endothelial dysfunction as measured by impair-
ment in flow-mediated dilatation occurred in 10 minutes.
Herrera et al [30] who measured plasma MDA in
hemodialysis patients 1 hour following iron sucrose ad-
ministration found levels to be significantly increased.
Roob et al [15] found plasma MDA to peak within
30 minutes after iron sucrose. Tovbin et al [31] found ad-
vanced protein oxidation products to be increased within
3 to 5 minutes after iron sucrose. Taken together these
data support the notion that oxidative stress occurs very
early after iron sucrose administration, at a time point
when substantial transferrin is available to bind to free
iron. Also, direct endothelial toxicity may occur indepen-
dent of transferrin saturation in subjects treated with iron
sucrose.
Our data are strikingly similar to that reported by
Zager et al [10] in mouse proximal tubular segments,
cultured human proximal tubular cells and bovine aortic
endothelial cells which demonstrate mitochondrial toxi-
city, cytotoxicity, and lipid peroxidation with intravenous
irons and substantial heterogeneity among iron prepara-
tions. Although each of the irons tested (iron dextran,
iron oligosaccharide, iron gluconate, and iron sucrose)
increased oxidative stress, the pattern of cytotoxicity was
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Fig. 4. Proposed pathway of injury as envisioned initially (bold arrows)
and as modified by the results of the trial (dashed arrows).
quite different. Thus, lethal cell injury as assessed by lac-
tate dehydrogenase (LDH) release in mouse and human
tubular cells was seen only with iron sucrose, but not with
iron dextran or sodium ferric gluconate, on 1 hour incu-
bation. After incubation for 16 hours, lethal cell injury
was more common with iron sucrose. Cell viability after
72 hours of iron exposure was least with iron sucrose, in-
termediate with sodium ferric gluconate and most with
iron dextran. The authors showed with a series of exper-
iments that the generation of oxidative stress with iron
sucrose was dependent on mitochondrial respiration, but
not free iron—oxidative stress was not blocked by the
iron chelator, desferoxamine. Furthermore, cytotoxicity
was protected by reduced glutathione, not by its antiox-
idant effect, but by providing cellular protection, similar
to glycine, in the setting of adenosine triphosphate (ATP)
depletion.
The initial pathway for renal injury we envisioned is
shown by bold arrows in Figure 4. However, results of the
study confirm what was initially proposed by Zager et al.
Thus, modification of the model is required to explain the
results as shown by the dashed arrows. The data in hu-
mans confirm the suggestion of Zager et al that there was
direct renal injury with injected iron sucrose. Whereas
administration of NAC resulted in reduction of oxidative
stress there was no protection from injury due to direct
drug-induced toxicity. Furthermore, the injury itself could
have led to production of oxidative stress therefore NAC
was insufficient in blocking oxidative stress completely.
Data are emerging that show differences between in-
travenous iron preparations. For example, Sengoelge
et al [32] have demonstrated greater impairment in neu-
trophil migration when incubated in vitro in iron su-
crose compared to sodium ferric gluconate. Besides the
well-known increased incidence of allergic events and
deaths with iron dextrans [33], there are other impor-
tant differences in pharmacokinetics such as differences
in molecular weights and plasma half lives, between intra-
venous irons. Comparative toxicity in humans is therefore
needed before our data can be generalized to other forms
of intravenous irons.
Animal data suggest the association of iron exposure,
generation of oxidative stress, and renal injury [11]. Low,
noncytolytic doses of oxidants such as hydrogen perox-
ide do not exert a hemodynamic effect or ultrastructural
abnormalities by electron microscopy, but have a pro-
found 50-fold increase in urinary protein excretion [34].
The glomerular epithelial cell interacts with the base-
ment membrane via integrin receptors, the distribution
of which can be altered by oxidants, perhaps leading to
functional changes [35]. Furthermore, oxidative modifi-
cation of membrane proteins could directly impair perms-
electivity of the glomerulus. In animals with the passive
Heymann nephritis model of membranous nephropathy,
treatment with the iron-chelating agent, desferroxamine,
abrogates proteinuria [36]. Importantly, generation of ox-
idative stress in the kidney in animals can lead to a tran-
sient increase in proteinuria. We believe that the transient
increase in proteinuria that mirrors the systemic and re-
nal generation of oxidative stress is suggestive of what
has been seen in animals [37]. Since proteinuria could be
of tubular or glomerular origin and we did not perform
studies to make this distinction, we cannot be certain as to
independent effect or iron sucrose on glomerular perms-
electivity. Further studies are planned to examine this
issue.
Renal biopsies from patients with nephrotic syndrome
and/or CKD revealed higher iron accumulation in the
proximal tubular lysosomes of patients with nephrotic
syndrome than nonnephrotic patients. The extent of
tubular damage correlates with the amount of iron in
lysosomes, and suggests the association of iron and mor-
phological injury to the kidney [38]. Long-term expo-
sure to iron in animals can cause tubulointerstitial fibrosis
[39]. Also, epidemiologic data in patients with CKD on
hemodialysis suggest the association of increased iron ex-
posure and atherosclerosis as assessed by carotid intima
thickness [16]. Concerns have been raised about intra-
venous iron sucrose treatment, occurrence of neutrophil
dysfunction and the risk of infectious complications [40].
Given the short term exposure to intravenous iron, the
long-term implications of our data are unclear. However,
on a positive note, we did not observe within 1 week
an increase in urinary MCP-1 levels, a marker of renal
inflammation.
Finally, iron administration can have benefits indepen-
dent of increase in hemoglobin concentration on physical
performance [41], cognitive function [42], basal ganglia
function [43], temperature regulation [44], and immune
function [45]. These hemoglobin-independent benefits of
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iron need to be better defined in the population of CKD
patients. Although our study was not powered to detect
improvement in quality of life parameters, we found, un-
expectedly, an improvement in pain score within 1 week.
There was also a trend toward improvement in physical
performance. These changes will need to be confirmed in
future trials.
Our study serves to establish a research model of tran-
sient renal injury with the use of intravenous iron. Future
studies will investigate the comparative effect of avail-
able intravenous irons, the dose-response relationship to
injury of such iron preparations, and emerging therapies
to protect against such injury. For example, if a dose-
response relationship between intravenous iron and renal
injury exists, as appears to be the case with in vitro models,
caution should be exercised with the use of higher dose
intravenous irons currently being used. The latter may
accelerate the loss of renal function in CKD patients or
residual renal function in patients on renal replacement
therapies.
In the clinical context, our study raises some concerns
regarding the use of intravenous iron preparations in gen-
eral, and iron sucrose in particular, in patients with stages
3 and 4 CKD. On one hand, it is possible that the tran-
sient injury by intravenous iron sucrose is outweighed by
the benefits of iron repletion and repair of anemia. On
the other, it is possible that the oxidative stress and direct
injury so generated increases the loss of renal function
and accelerates cardiovascular disease. Most important,
long-term studies on assessment of risk and benefits of
intravenous iron are needed to better determine the bal-
ance between efficient repair of anemia and exposure to
injury.
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